rawfin.tv
Maxim Group Reaffirms Buy Rating for Moleculin Biotech (MBRX.US), $10 Target
MarketsstocksAI Generated

Maxim Group Reaffirms Buy Rating for Moleculin Biotech (MBRX.US), $10 Target

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Maxim Group has reiterated its 'Buy' rating for Moleculin Biotech (MBRX.US), maintaining a target price of $10 per share. This analyst coverage signals continued confidence in the company's prospects and potential for stock appreciation.

StocksAnalyst RatingBiotechInvestment Thesis

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks